【摘 要】
：
Few treatment options are available for advanced non-small cell lung cancer. patients who have failed of gefitinib or erlotinib treatment in second/third-line t
【出 处】
：
第十五届全国临床肿瘤学大会暨2012年CSCO学术年会
论文部分内容阅读
Few treatment options are available for advanced non-small cell lung cancer. patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to evaluate the feasibility and safety of retreatment the same EGFR-tyrosine kinase inhibitor(EGFR-TKI) after the failure of gefitinib or erlotinib based on the data from our hospital. The clinical data of 33 patients with advanced NSCLC who were admitted to Zhejiang Cancer Hospital from January 2007 to July 2011 were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method.
其他文献
目的:分析原发性肺癌的临床特点.方法:回顾性分析521例确诊为原发性肺癌且有完整资料患者的临床特点,采用卡方分析、方差分析和t检验对其临床特点进行分析.结果:男性377例、
文章旨在观察贝伐单抗联合培美曲塞加铂类一线治疗晚期非小细胞肺癌的临床疗效及其毒副反应.通过选取晚期非小细胞肺癌非鳞癌患者16例为实验组，所有患者均接受贝伐单抗联合培
本文通过回顾性分析老年肺癌的临床、病理、分子特征,旨在探讨其对老年肺癌的诊断和治疗的指导意义.分析结果表明老年患者初始发病的临床表现谱广，尤其非特异性呼吸道症状(如
目的:观察体部伽玛刀联合化疗治疗不能手术的局部晚期非小细胞肺癌(NSCLC)的疗效、不良反应及生存期.方法:78例局部晚期非小细胞肺癌采用体部伽玛刀联合化疗治疗,伽玛刀治疗
初次见面/你还是个小孩/笑容总是24小时挂在脸上/稀松的羽毛/还是透明的二度见你/羽毛已渐渐丰满/亦如你的心灵/微笑也不再幼稚/而是拥有快乐的炫耀现在/应该仰头看你/高高地
肺癌的发病与死亡率已越居各类恶性肿瘤之首,以呼吸困难为主要临床表现,大气道阻塞为主要特征的晚期中心型肺癌,也日益增多,为了探讨射频技术在肿瘤性气道阻塞中的疗效,本文
文章旨在解临床规范诊疗现况,提高小细胞肺癌(SCLC)治疗水平.通过随机抽取6家医院(其中三级医院3家、二级医院3家),对2010.1-2012.4间,全部SCLC165例的诊治情况进行回顾性调
Limited retrospective or prospective studies showed that the patients may benefit from the single-agent or combination chemotherapy in small cell lung cancer(SC
小细胞肺癌(SCLC)初治敏感,易复发,预后不佳.本文旨在比较拓扑替康、含铂联合化疗及其他单药化疗在敏感复发SCLC患者二线治疗中的疗效与安全性.通过回顾分析83例敏感复发接受